Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galactic53: Viltolarsen in DMD
NCT04956289Phase 2Completed
- Sponsor
- NS Pharma, Inc.
- Start
- Jul 2021
- Primary completion
- Jun 2023
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of viltolarsen in Duchenne muscular dystrophy (DMD), sponsored by NS Pharma, Inc. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events at 48 weeks, Number of Participants With Treatment Emergent Adverse Events by Maximum Severity at 48 weeks and 2 more. Started Jul 2021; status: completed.
02
Drugs
viltolarsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT04956289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04956289.